Huiyu Pharmaceutical: Clinical Trial Application for Injectable HY07121 (Subcutaneous Injection) Accepted
Huayu Pharmaceutical's subsidiary, Huayu Haiyue, has received approval from China's National Medical Products Administration to begin clinical trials for HY07121, a novel subcutaneous injection for advanced solid tumors. This innovative biologic is a triple-target fusion protein designed to combat PD-1, TIGIT, and IL-15/IL-15Rα, aiming to enhance patient convenience and reduce side effects. Currently, no other triple-target products are available on the market. AI
IMPACT This development signifies progress in targeted cancer therapies, potentially offering new treatment options with improved patient outcomes.